A
Alcyone Lifesciences
Pioneers next-generation intra-CSF CNS precision gene-based therapeutics for complex neurological conditions
About Alcyone Lifesciences
Alcyone Therapeutics is a biotechnology company focused on developing next-generation genetic therapies for severe neurological disorders. The company leverages its expertise in genetic therapy research, cerebrospinal fluid (CSF) biofluid dynamics, bioengineering, and chemistry, manufacturing, and controls (CMC) to create transformative treatments. Alcyone's core innovation lies in its precision intra CSF dosing and delivery system, which aims to improve the efficacy of treatments for complex neurological conditions. The company operates in the biotechnology market, primarily serving patients with severe neurological disorders. Alcyone's business model involves collaborating with research institutions, such as The Abigail Wexner Research Institute at Nationwide Hospital, to develop and commercialize its gene-based therapeutics. Revenue is generated through partnerships, grants, and potentially future sales of approved therapies.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Ayer, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 60.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Genetics and genomics, Spinout, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Sep 2025 | $85M | — | Biogen | ↗ |
| LATE VC✓Equity / VC | Apr 2025 | $0 | — | Nationwide Children's Hospital | ↗ |
Growth signals
Latest recorded traffic for Alcyone Lifesciences is 20 monthly website visits, down 98.8% over the last three months. Alcyone Lifesciences's team declined 60.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Edgar Jannotta- HPHarbor Light Capital Partners
Series B and later2 investors entered at this stage
RTW Investments
Nationwide Children's Hospital
Other known investors3 additional known investors
Biogen
Cornell Tech
Cornell University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Alcyone Lifesciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Alcyone Lifesciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.